Simcere Pharmaceutical Group (HKSE:02096) Scaled Net Operating Assets : 0.52 (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Simcere Pharmaceutical Group Scaled Net Operating Assets?

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Simcere Pharmaceutical Group's operating assets for the quarter that ended in Dec. 2023 was HK$9,664 Mil. Simcere Pharmaceutical Group's operating liabilities for the quarter that ended in Dec. 2023 was HK$2,408 Mil. Simcere Pharmaceutical Group's Total Assets for the quarter that ended in Jun. 2023 was HK$13,880 Mil. Therefore, Simcere Pharmaceutical Group's scaled net operating assets (SNOA) for the quarter that ended in Dec. 2023 was 0.52.

Simcere Pharmaceutical Group Scaled Net Operating Assets Historical Data

The historical data trend for Simcere Pharmaceutical Group's Scaled Net Operating Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Simcere Pharmaceutical Group Scaled Net Operating Assets Chart

Simcere Pharmaceutical Group Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Scaled Net Operating Assets

Get a 7-Day Free Trial

0.54

0.84

0.56

0.54

0.60

Simcere Pharmaceutical Group Semi-Annual Data
	Dec17	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Scaled Net Operating Assets	Get a 7-Day Free Trial							0.60	0.45	0.58	0.70	0.52

Competitive Comparison of Simcere Pharmaceutical Group's Scaled Net Operating Assets

For the Drug Manufacturers - Specialty & Generic subindustry, Simcere Pharmaceutical Group's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Simcere Pharmaceutical Group's Scaled Net Operating Assets Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Simcere Pharmaceutical Group's Scaled Net Operating Assets distribution charts can be found below:

* The bar in red indicates where Simcere Pharmaceutical Group's Scaled Net Operating Assets falls into.

Simcere Pharmaceutical Group Scaled Net Operating Assets Calculation

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Simcere Pharmaceutical Group's Scaled Net Operating Assets (SNOA) for the fiscal year that ended in Dec. 2023 is calculated as

	Scaled Net Operating Assets (SNOA)		(A: Dec. 2023 )
=	(Operating Assets (A: Dec. 2023 )	-	Operating Liabilities (A: Dec. 2023 ))	/	Total Assets (A: Dec. 2022 )
=	(9663.939	-	2408.181)	/	12048.181
=	0.60

where

	Operating Assets		(A: Dec. 2023 )
=	Total Assets	-	Cash, Cash Equivalents, Marketable Securities
=	11871.512	-	2207.573
=	9663.939

	Operating Liabilities		(A: Dec. 2023 )
=	Total Liabilities	-	Long-Term Debt & Capital Lease Obligation	-	Short-Term Debt & Capital Lease Obligation
=	3971.436	-	365.588	-	1197.667
=	2408.181

Simcere Pharmaceutical Group's Scaled Net Operating Assets (SNOA) for the quarter that ended in Dec. 2023 is calculated as

	Scaled Net Operating Assets (SNOA)		(Q: Dec. 2023 )
=	(Operating Assets (Q: Dec. 2023 )	-	Operating Liabilities (Q: Dec. 2023 ))	/	Total Assets (Q: Jun. 2023 )
=	(9663.939	-	2408.181)	/	13879.674
=	0.52

where

	Operating Assets		(Q: Dec. 2023 )
=	Total Assets	-	Cash, Cash Equivalents, Marketable Securities
=	11871.512	-	2207.573
=	9663.939

	Operating Liabilities		(Q: Dec. 2023 )
=	Total Liabilities	-	Long-Term Debt & Capital Lease Obligation	-	Short-Term Debt & Capital Lease Obligation
=	3971.436	-	365.588	-	1197.667
=	2408.181

Simcere Pharmaceutical Group Scaled Net Operating Assets Related Terms

Thank you for viewing the detailed overview of Simcere Pharmaceutical Group's Scaled Net Operating Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Simcere Pharmaceutical Group (HKSE:02096) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Simcere Pharmaceutical Group Ltd (HKSE:02096) » Definitions » Scaled Net Operating Assets

Traded in Other Exchanges

S2P:Germany

Address

No. 699-18, Xuanwu Road, Xuanwu District, Jiangsu, Nanjing, CHN, 210042

Website

https://www.simcere.com

Simcere Pharmaceutical Group Ltd is engaged in the R&D, production and commercialization of pharmaceuticals focused on generic pharmaceuticals. It has a diversified product portfolio focused on therapeutic areas, including, oncology (including cell therapy), nervous system diseases, autoimmune diseases and antiinfection. The company's products include Endostar, Enweida, Iremod, Sanbexin and Others.

Executives

Wang Xi	2305 Beneficiary of a trust
Ren Jinsheng	2202 Interest of your spouse
Right Wealth Holdings Limited	2501 Other
Wang Xi	2501 Other
Simcere Investments Group Limited	2501 Other
Excel Investments Group Limited	2501 Other
Simcere Pharmaceutical Holding Limited	2501 Other
Simcere Holding Limited	2501 Other
Artking Global Limited	2501 Other
Ren Zhen	2501 Other
Ren Yong	2501 Other
Ren Weidong	2501 Other
Peng Suqin	2501 Other
P&h Holdings Group Ltd.	2501 Other
Li Shimeng	2501 Other

Simcere Pharmaceutical Group (HKSE:02096) Headlines

No Headlines